In Silico Clinical Trials Market Size, Share & Trends Analysis Report By Therapeutic Area (Oncology, Infectious Diseases), By Phase (Phase I, II, III), By Industry (Medical Devices, Pharmaceutical), And Segment Forecasts, 2022 - 2030

In Silico Clinical Trials Market Growth & Trends

The global in silico clinical trials market size is expected to reach USD 5.1 billion by 2030 and is projected to expand at a CAGR of 7.4% over the forecast period, according to a new report by Grand View Research, Inc. Traditional clinical trials require huge expenditure to conduct research. Moreover, a high number of drugs and medical devices fail in the clinical trial owing to the lack of safety and efficacy, which creates huge losses for the clinical trial sponsors. These factors promote the demand for in silico clinical trials, to understand the behavior of drugs or medical devices in humans. In silico clinical trials use simulation techniques to understand the efficacy and safety of a drug or medical device.

This reduces the chances of adverse reactions, thus, improving the safety and efficacy of research studies. The market players are making significant investments to provide new treatments to the people. For instance, in June 2021, In silico Medicine raised USD 255 million in funding to boost its R&D for drug discovery, through in silico studies. The demand for in silico clinical trials was also improved during the pandemic as there was a temporary shutdown of clinical research sites and several studies for vaccines and therapeutic agents for COVID-19 were performed through in silico research models. Such actions are likely to have a positive impact on market growth.

In Silico Clinical Trials Market Report Highlights

  • The medical device segment dominated the market in 2021 owing to the fact that the majority of in silico trials are performed for medical devices globally
  • The phase II segment accounted for the largest market revenue share in 2021
  • The oncology therapeutic area segment accounted for the largest market revenue share in 2021
  • The cancer clinical trials have high chances of incurring adverse effects on patients, which promotes the demand for in silico trials for cancer
  • North America held the largest revenue share in 2021 due to the presence of several global players operating in the market
  • In addition, a significant number of in silico trials are performed in the U.S., which further contributes to the growth of the regional market
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Industry
1.1.2 Therapeutic Area
1.1.3 Phase
1.1.4 Regional Scope
1.1.5 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective - 1: Understanding the market dynamics
1.10.2 Objective - 2: Understanding the market estimates and forecasts
1.10.3 Objective - 3: Understanding the attributes such as strategy framework
1.10.4 Objective - 4: Understanding the key service and application scopes to conclude on the market size
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Insilico Clinical Trials Market : Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Driver Analysis
3.2.1 Cost Efficiency Associated with Insilico Clinical
Trials Compared to Traditional Clinical Trials
3.2.2 Growing Trend of Eliminating/Reducing Animal
Testing
3.2.3 Increasing Technological Advancement in the
Insilico Clinical Trials Market
3.3 Market Restraint Analysis
3.3.1 Protein Flexibility Issues, Molecule
Conformation and Promiscuity May Hinder
Accurate Predictions, thus limiting its Adoption
3.3.2 Limited Awareness in the Developing
Economies
3.4 Penetration & Growth Prospect Mapping
3.5 Porter’s Five Forces Analysis
3.6 PESTEL Analysis
Chapter 4 Insilico Clinical Trials Market : Industry Segment Analysis
4.1 Insilico Clinical Trials : Market Share Analysis, 2021 & 2030
4.2 Medical devices
4.2.1 Medical devices market, 2018 - 2030 (USD Million)
4.3 Pharmaceutical
4.3.1 Pharmaceutical market, 2018 - 2030 (USD Million)
Chapter 5 Insilico Clinical Trials Market : Therapeutic Segment Analysis
5.1 Insilico Clinical Trials : Market Share Analysis, 2021 & 2030
5.2 Oncology
5.2.1 Oncology market, 2018 - 2030 (USD Million)
5.3 Infectious disease
5.3.1 Infectious disease market, 2018 - 2030 (USD Million)
5.4 Hematology
5.4.1 Hematology market, 2018 - 2030 (USD Million)
5.5 Cardiology
5.5.1 Cardiology market, 2018 - 2030 (USD Million)
5.6 Dermatology
5.6.1 Dermatology market, 2018 - 2030 (USD Million)
5.7 Neurology
5.7.1 Neurology market, 2018 - 2030 (USD Million)
5.8 Diabetes
5.8.1 Diabetes market, 2018 - 2030 (USD Million)
5.9 Others
5.9.1 Others market, 2018 - 2030 (USD Million)
Chapter 6 Insilico Clinical Trials Market: Phase Segment Analysis
6.1 Insilico Clinical Trials: Market Share Analysis, 2021 & 2030
6.2 Phase I
6.2.1 Phase I, 2018 - 2030 (USD Million)
6.3. Phase II
6.3.1 Phase II, 2018 - 2030 (USD Million)
6.4. Phase III
6.4.1 Phase III, 2018 - 2030 (USD Million)
6.5. Phase IV
6.5.1 Phase IV, 2018 - 2030 (USD Million)
Chapter 7 Insilico Clinical Trials Market : Region Segment Analysis
7.1 Insilico Clinical Trials : Market Share Analysis, 2021 & 2030
7.2 North America
7.2.1 North America insilico clinical trials market, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. insilico clinical trials market, 2018 - 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada insilico clinical trials market, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe insilico clinical trials market, 2018 - 2030 (USD Million)
7.3.2 U.K.
7.3.2.1 U.K. insilico clinical trials market, 2018 - 2030 (USD Million)
7.3.3 Germany
7.3.3.1 Germany insilico clinical trials market, 2018 - 2030 (USD Million)
7.3.4 France
7.3.4.1 France insilico clinical trials market, 2018 - 2030 (USD Million)
7.3.5 Italy
7.3.5.1 Italy insilico clinical trials market, 2018 - 2030 (USD Million)
7.3.6 Spain
7.3.6.1 Spain insilico clinical trials market, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific insilico clinical trials market, 2018 - 2030 (USD Million)
7.4.2 India
7.4.2.1 India insilico clinical trials market, 2018 - 2030 (USD Million)
7.4.3 China
7.4.3.1 China insilico clinical trials market, 2018 - 2030 (USD Million)
7.4.4 Japan
7.4.4.1 Japan insilico clinical trials market, 2018 - 2030 (USD Million)
7.4.5 Australia
7.4.5.1 Australia insilico clinical trials market, 2018 - 2030 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea insilico clinical trials market, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America insilico clinical trials market, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil insilico clinical trials market, 2018 - 2030 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico insilico clinical trials market, 2018 - 2030 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina insilico clinical trials market, 2018 - 2030 (USD Million)
7.5.5 Colombia
7.5.5.1 Colombia insilico clinical trials market, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 MEA insilico clinical trials market, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa insilico clinical trials market, 2018 - 2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia insilico clinical trials market, 2018 - 2030 (USD Million)
7.6.4 UAE
7.6.4.1 UAE insilico clinical trials market, 2018 - 2030 (USD Million)
Chapter 8 Company Profiles
8.1 Certara, Inc.
8.1.1 Company overview
8.1.2 Financial performance
8.1.3 Service benchmarking
8.1.4 Strategic initiatives
8.2 Novadiscovery Sas
8.2.1 Company overview
8.2.2 Financial performance
8.2.3 Service benchmarking
8.2.4 strategic initiatives
8.3 Insilico Medicine, Inc.
8.3.1 Company overview
8.3.2 Service benchmarking
8.3.3 Strategic initiatives
8.4 Dassault Systemes SE
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Servcie benchmarking
8.4.4 Strategic initiatives
8.5 GNS Healthcare Inc .
8.5.1 Company overview
8.5.2 Financial performance
8.5.3 Service benchmarking
8.5.4 Strategic initiatives
8.6 The AnyLogic Company
8.6.1 Company overview
8.6.2 Financial performance
8.6.3 Service benchmarking
8.6.4 Strategic initiatives
8.7 InSilicoTrials
8.7.1 Company overview
8.7.2 Financial performance
8.7.3 Service benchmarking
8.7.4 Strategic initiatives
8.8 Immunetrics Inc.
8.8.1 Company overview
8.8.2 Financial performance
8.8.3 Service benchmarking
8.8.4 Strategic initiatives
8.9 Nuventra Pharma Sciences
8.9.1 Company overview
8.9.2 Service benchmarking
8.9.3 Strategic initiatives
8.10 Abzena Ltd.
8.10.1 Company overview
8.10.2 Service benchmarking
8.10.3 Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings